I’m trying to advance the discussion, but apparently most are still stuck at “these are not even vaccines”. Yeah, we knew that the moment we visited a manufacturer’s website, which is among the first reasonable things to do. I hope this will help closing that debate and will ease stepping further down the rabbit hole. Watch how many will find out these things from me rather than from the original source!

mRNA doesn’t alter DNA?

mRNA is just as critical as DNA.

source: Moderna

Without mRNA, your genetic code would never get used by your body. Proteins would never get made. And your body wouldn’t – actually couldn’t – perform its functions. Messenger ribonucleuc acid, or mRNA for short, plays a vital role in human biology, specifically in a process known as protein synthesis. mRNA is a single-stranded molecule that carries genetic code from DNA in a cell’s nucleus to ribosomes, the cell’s protein-making machinery.

Moderna

Our Operating System

Recognizing the broad potential of mRNA science, we set out to create an mRNA technology platform that functions very much like an operating system on a computer. It is designed so that it can plug and play interchangeably with different programs. In our case, the “program” or “app” is our mRNA drug – the unique mRNA sequence that codes for a protein.

We have a dedicated team of several hundred scientists and engineers solely focused on advancing Moderna’s platform technology. They are organized around key disciplines and work in an integrated fashion to advance knowledge surrounding mRNA science and solve for challenges that are unique to mRNA drug development. Some of these disciplines include mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering.

Our mRNA Medicines – The ‘Software of Life’

When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.

Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.

We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.

Within a given modality, the base components are generally identical across development candidates – formulation, 5’ region and 3’ region. Only the coding region varies based on the protein/s the potential medicine is directing cells to produce.

Learn how our Research Engine and Early Development Engine are enabling us to fully maximize the promise of mRNA to meaningfully improve how medicines are discovered, developed and manufactured.

‘Life is just a flow of information. And we’re interfering with it”

Overcoming Key Challenges

Using mRNA to create medicines is a complex undertaking and requires overcoming novel scientific and technical challenges. We need to get the mRNA into the targeted tissue and cells while evading the immune system. If the immune system is triggered, the resultant response may limit protein production and, thus, limit the therapeutic benefit of mRNA medicines. We also need ribosomes to think the mRNA was produced naturally, so they can accurately read the instructions to produce the right protein. And we need to ensure the cells express enough of the protein to have the desired therapeutic effect. 

Our multidisciplinary platform teams work together closely to address these scientific and technical challenges. This intensive cross-functional collaboration has enabled us to advance key aspects of our platform and make significant strides to deliver mRNA medicines for patients.

MODERNA

SOFTWARE OF LIFE™ Research and Design Services

Our mRNA RESEARCH ENGINE™ services enable us to advance new product ideas into development candidates via our drug discovery efforts, and includes infrastructure to enable rapid supply of thousands of preclinical mRNAs for research involving in vitro and in vivo experiments in order to accelerate programs from idea to development candidate designation.

 

mRNA Design Studio™ – Digital Design and Ordering of mRNA for Research

Our mRNA Design Studio enables rapid design of multiple mRNAs.

As our scientists create new mRNA concepts, they can design mRNAs for research and testing, within days, using our proprietary systems. As the Digital Biotech Company™, we utilize the software-like property of mRNA in our proprietary, web-based mRNA Design Studio. Our scientists request mRNAs for a specific protein, and the protein target is automatically converted to an initial optimized mRNA sequence. Using our Sequence Designer module, they can tailor entire mRNAs from the 5’-UTR to the coding region to the 3’-UTR based on our ever-improving proprietary learnings. The mRNA sequence is then further optimized using our proprietary bioinformatics algorithms. Our digital ordering then ensures rapid and accurate transmission of sequences to our modular synthesis robotics.

Our proprietary in-house digital application suite contains a Sequence Designer module to tailor an entire mRNA, with ever-improving rule sets that contain our accumulated learning about mRNA design. Drug Design Studio utilizes cloud-based computational capacity to run various algorithms we have developed to design each mRNA sequence. The utility of cloud-based capacity allows us to provide flexible computational capacity on demand, allowing the Research Engine to power parallel intake and design of multiple mRNA sequences.

Moderna’s Research Engine

Our Research Engine combines proprietary digital drug design tools and a highly automated production facility to enable Moderna and our strategic collaborators to move mRNA medicines swiftly through the research stage, from idea to development candidate nomination.

Scientists can begin by selecting any protein in the human proteome to be further engineered, including antibodies, or they can design novel proteins like traps, fusion proteins, or completely novel scaffolds and sequences. All can be designed to explore previously undruggable pathways.

The Drug Design Studio integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput mRNA pre-clinical production facility manages the manufacturing of mRNA constructs and delivers them in just weeks.

MODERNA

Is Humanity even trying to survive?!

PS: Some people wonder why the vids above are available on their website but unlisted on their Youtube.
It’s because they know you won’t look for them on their site, mostly potential partners will.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We gave up on our profit shares from masks, if you want to help us, please use the donation button!
We think frequent use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness.
Get it here!

It’s a bit too late, but you can start freaking out

Initially I didn’t pay much attention to these reports because first ones were pretty vague and seemed unsubstantiated. They kind of were.
But then they started to become more and more detailed, coherent and very specific. My own research on #biohacking started to intersect more often, to the point where today they almost coincide.

To better understand where I’m coming from, your journey needs to start here:

Yes, they CAN vaccinate us through nasal test swabs AND target the brain (Biohacking P.1)

and here:

OBAMA, DARPA, GSK AND ROCKEFELLER’S $4.5B B.R.A.I.N. INITIATIVE – BETTER SIT WHEN YOU READ

After you read these, it’s much easier to dive into these new findings:

SOURCE
SOURCE
“cross the blood-brain barrier” as in “ Yes, they CAN vaccinate us through nasal test swabs AND target the brain

Profusa, Inc. Awarded $7.5M DARPA Grant to Develop Tissue-integrated Biosensors for Continuous Monitoring of Multiple Body Chemistries


NEWS PROVIDED BY Profusa, Inc. 

Jul 12, 2016, 08:30 ET


SOUTH SAN FRANCISCO, Calif., July 12, 2016 /PRNewswire/ — Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that it was awarded a $7.5 million dollar grant from the Defense Advanced Research Projects Agency (DARPA) and the U.S. Army Research Office (ARO) to develop implantable biosensors for the simultaneous, continuous monitoring of multiple body chemistries. Aimed at providing real-time monitoring of a combat soldier’s health status to improve mission efficiency, the award supports further development of the company’s biosensor technology for real-time detection of the body’s chemical constituents. DARPA and ARO are agencies of the U.S. Department of Defense focused on the developing emerging technologies for use by the military.

SOURCE

“Profusa’s vision is to replace a point-in-time chemistry panel that measures multiple bio­markers, such as oxygen, glucose, lactate, urea, and ions with a biosensor that provides a continuous stream of wireless data,” said Ben Hwang, Ph.D., Profusa’s chairman and chief executive officer. “DARPA’s mission is to make pivotal investments in breakthrough tech­nologies for national security. We are gratified to be awarded this grant to accelerate the development of our novel tissue-integrating sensors for application to soldier health and peak performance.”

Tissue-integrating Biosensors for Multiple Biomarkers
Supported by DARPA, ARO and the National Institutes of Health, Profusa’s technology and unique bioengineering approach overcomes the largest hurdle in long-term use of biosensors in the body: the foreign body response. Placed just under the skin with a specially designed injector, each tiny biosensor is a flexible fiber, 2 mm-to-5 mm long and 200-500 microns in dia­meter. Rather than being isolated from the body, Profusa’s biosensors work fully integrated within the body’s tissue — without any metal device or electronics — overcoming the effects of the foreign body response for more than one year.

Each biosensor is comprised of a bioengineered “smart hydrogel” (similar to contact lens mater­ial) forming a porous, tissue-integrating scaffold that induces capillary and cellular in-growth from surrounding tissue. A unique property of the smart gel is its ability to luminesce upon exposure to light in proportion to the concentration of a chemical such as oxygen, glucose or other biomarker.

“Long-lasting, implantable biosensors that provide continuous measurement of multiple body chemistries will enable monitoring of a soldier’s metabolic and dehydration status, ion panels, blood gases, and other key physiological biomarkers,” said Natalie Wisniewski, Ph.D., the principal investigator leading the grant work and Profusa’s co-founder and chief technology officer. “Our ongoing program with DARPA builds on Profusa’s tissue-integrating sensor that overcomes the foreign body response and serves as a technology platform for the detection of multiple analytes.”

Lumee Oxygen Sensing System™
Profusa’s first medical product, the Lumee Oxygen Sensing System, is a single-biomarker sensor designed to measure oxygen. In contrast to blood oxygen reported by other devices, the system incorporates the only technology that can monitor local tissue oxygen. When applied to the treatment of peripheral artery disease (PAD), it prompts the clinician to provide therapeutic action to ensure tissue oxygen levels persist throughout the treatment and healing process.

Pending CE Mark, the Lumee system is slated to be available in Europe in 2016 for use by vascular surgeons, wound-healing specialists and other licensed healthcare providers who may benefit in monitoring local tissue oxygen. PAD affects 202 million people worldwide, 27 million of whom live in Europe and North America, with an annual economic burden of more than $74 billion in the U.S. alone.

Profusa, Inc.
Profusa, Inc., based in South San Francisco, Calif., is leading the development of novel tissue-integrated sensors that empowers an individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the body’s response to foreign material for long-term use, its technology promises to be the foundational platform of real-time biochemical detection through the development of tiny bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. See http://www.profusa.com for more information.

The research is based upon work supported by DARPA, the Biological Technologies Office (BTO), and ARO grant [W911NF-16-1-0341]. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of DARPA, BTO, the ARO, or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright annotation thereon.

SOURCE Profusa, Inc.

Related Links

http://www.profusa.com

SOURCE
SOURCE

I SAVED THE BEST FOR LAST

SOURCE
and then you wonder why…

So I can’t say with 100% certitude that what DARPA did and what people found are one and the same thing, but this is the closest you can get to 100%, and 200% x reason to freak out.

I will keep adding resources and details here, but my point is made.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

If you enabled this Covidiocracy in any way, I’m sorry for you! Even if you have a long life ahead of you, you’ll never experience peace of soul and happiness again.
And in no way you’re welcome to rule over or dictate to any living soul.

BONUS:

DOWNLOAD PDF

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

WTH ever happened to “verify from three independent sources”?

These guys:

… just said this:

SHORT ATTENTION SPAN VERSION
FULL VERSION

Amazing list of investors, btw!

UPDATE #4: JUNE 4, 2021

BREAKING! 2ND BATCH OF FAUCI E-MAILS

UPDATE #1 : WE’VE JUST BEEN CONFIRMED BY THE UNFORTUNATE AMATEUR PROPAGANDISTS DISGUISED AS FRANCE PRESSE FACT-CHECKERS

SOURCE

ALL THEY HAVE IS A “POST IT” FROM CHINA!

Ah, and a “Nature publication”, I loled. o_O
What kind of people use “there is no question” as scientific argument/evidence? Pseudo-scientists, snake-oil salesmen and con artists of all kinds.

The sub-zeroes from the CBS-affiliate WUSA9 try to lend a helping hand to their owners, but they double down for us:

They link, as evidence, to this NIH page which ONLY MENTIONS GENBANK, which is the same fridge on which China stuck that “post it” note.
THAT IS ALL THEY HAVE.

WTH ever happened to “verify from three independent sources”?
It used to be Rule #0 in journalism, back when I studied it in college.

UPDATE2:
I discovered this when the video was already up…

Source

“Most of our readers are interested in consumer DNA testing for genealogy and ancestry research. Illumina played a massive role in making these services affordable. All the big DNA testing companies use Illumina’s chip technology.
But some companies are even more closely intertwined with Illumina. I mention briefly in an article on who owns 23andMe that the chip company was an investor in the 2015 funding found of its customer.”

https://www.dataminingdna.com/

“If you’ve ever used 23andMeAncestry.com, or any other genetics-testing service, chances are that your genes were sequenced on machines made by the $25 billion biotech behemoth. Now the undisputed leader in the emerging field of DNA sequencing in the U.S., Illumina has outstripped its rivals by selling its sequencing hardware to medical researchers around the world.”

https://www.fastcompany.com/

As we’ve shown in previous reports, 23andMe is owned by Richard Branson and a former wife and current partner of Google’s founder Sergey Brin. She also happens to be the sister of YouTube CEO.

“23andMe is owned by a sizeable number of large investors spearheaded by Anne Wojcicki and Richard Branson. The list of investors with recent ownership stakes in the company includes Altimeter Capital, Fidelity, Casdin Capital, and Foresite Capital.
Since the company was founded in 2006, it has been involved in multiple funding rounds. There were at least 60 investors in 2020 before the merger, including GlaxoSmithKline and Sequoia Capital. Early investors include Alphabet (Google’s parent company) and WuXi Healthcare Ventures (a Chinese company).
When 23andMe merged with Richard Branson’s acquisition company, the existing stakeholders retained ownership of 81% of the merged company.”

dataminingdna.com

According to Wikipedia:

“In 2005, co-founder and former Chief Scientific Officer Anthony Czarnik sued Illumina; see Czarnik v. Illumina Inc.

In 2010, Cornell University and Life Technologies filed a lawsuit against Illumina, alleging that its microarray products infringed on eight patents held by the university and exclusively licensed to the start-up. The case was settled in April 2017 without any finding of fault. In September 2017 both parties asked to have the settlement reviewed, with Cornell accusing both Illumina and Life Technologies of misrepresentation and fraud.[44]

In February 2020, Illumina filed a patent infringement suit against BGI relating to its “CoolMPS” sequencing products.[48] In return BGI has filed patent infringement lawsuits for violation of federal antitrust and California unfair competition laws, claiming use of “fraudulent behavior” to obtain or enforce sequencing patents that it has asserted against BGI, preventing the firm from entering the US market.[49]

“BGI” as in…

BILL GATES’ & BIG TECH’S CHINESE DARLINGS: WORLD’S TOP DNA HARVESTERS, CLONERS, UIGHUR PERSECUTERS (BIOHACKING P.4)

Ah, also…

source

UPDATE 3:

Sharryl Atkinson investigates the source of the virus, finds out no one in US got samples in their lab, moves on trying to find the source of a virus that no one can provide samples / isolation / purification.

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

I survived many tough times focusing on the humor in them. And I find this highly amusing. But even more disturbing, when I look around and I see most people don’t flinch hearing such a claim.

Source

As for insurances and vaccines, the topic of that Forbes article… oh boy, oh boy… Check this out! And then THIS!

Follow up:

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

“In the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines.”

Three decades of messenger RNA vaccine development

Like teenagers the world over, Nobel Prize-winning scientist Ralph Steinman had absolutely no idea what he wanted to do when he grew up.

In a 2009 essay, the Canadian-born immunologist and cell biologist described his early school career as unfocused, only landing on an interest in biology and medicine while taking “almost every other course” at McGill University in Montreal while on scholarship as an undergraduate.

This latent interest eventually led him to Harvard Medical School, where he earned his M.D. (also on scholarship), and an internship and residency at Massachusetts General Hospital. In 1970, the young Steinman joined the Laboratory of Cellular Physiology and Immunology at Rockefeller University in New York City as a postdoctoral fellow under cell biologist and immunologist Zanvil A. Cohn. Steinman wanted to know what triggers the body’s immune system to kick into gear to initiate a response, a question few scientists at the time were asking.

Just three years later, while working with cells from the spleens of mice, Steinman and Cohn made the discovery that would shape Steinman’s future: the identification and role of a particular type of white blood cell that sets into motion and controls the body’s immune system. They termed these cells dendritic cells, after the branching, tree-like shape the cells can form.

By identifying this chief component that initiates and regulates an immune response, Steinman had discovered why, when, and how the body’s immune system reacts the way that it does, especially in the face of foreign pathogens. He’d discovered what amounted to the boss cell that kicks off immune reactions and tells other cells what to do and what not to do. Dendritic cells also play a role in autoimmune diseases, inflammation, allergies, and transplant rejections.

This discovery would revolutionize immunotherapy and eventually launch the new field of dendritic cell biology. But at the time, Steinman’s discovery was generally disregarded. Dendritic cells were considered little more than an obscure anomaly by much of the scientific community. To top it off, the cells were difficult to isolate, and low in frequency and abundance to boot. It would take more than 20 years and Steinman’s development of a new method to generate large numbers of dendritic cells for experimental use for the scientific community to finally verify and accept his theories.

His chances for surviving another year were estimated at less than five percent.

Steinman was especially interested in clinical applications for dendritic cells, dedicating much of his career toward the development of new medical therapies and treatments based on his research. His discovery led to the first therapeutic cancer vaccine in 1973, a dendritic cell-based immunotherapy for the treatment of prostate cancer. Other potential immunotherapies that have resulted include cancer and transplantation treatments and vaccines for HIV, malaria, tuberculosis, and the Epstein-Barr virus, some of which have reached clinical trials.

Steinman’s desire to see his research put into practical medical application cannot be overstated. Despite his gentle, almost grandfatherly way of speaking, he often expressed frustration at the slow speed at which experimental therapies escaped the confines of the lab and its theoretical animal and data models to reach actual patients. This impatience took on a new sense of urgency in 2007 when Steinman was diagnosed with Stage 4 (advanced) pancreatic cancer. By the time of his diagnosis, the cancer had already advanced beyond the pancreas and spread to Steinman’s lymph nodes. His chances for surviving another year were estimated at less than five percent.

So, Steinman went to work. In response to his illness, he designed and coordinated a single-case medical study with himself as the sole subject.

In addition to undergoing conventional surgery and chemotherapy, Steinman reached out to the international network of researchers in industry and academia he’d built over his decades-long career. Banding together for this common cause, he and his colleagues developed a variety of personalized cancer treatments, many based on his design and research, including vaccines developed from Steinman’s own tumor cells.

“With ten million persons afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines—either as therapeutic agents or as preventative measures—are hopeful indicators of progress in this field. This volume comprises invited chapters from world-renowned researchers and clinicians that shed light on recent steps forward in immunotherapeutic and preventive approaches for future cancer vaccines.” – Blackwell Publishing

A close-up look at a dendritic cell, the boss cell that kicks off immune reactions and tells other cells what to do and what not to do.

Despite his general impatience with the speed of the traditional scientific process, Steinman insisted on conducting his personal trial according to established protocols, filing mounds of paperwork with official channels and seeking appropriate permissions for untested therapies just like any other trial. Although his personalized experiment was not controlled, he wanted it well-organized and well-documented so his treatment attempts might not only find a cure for himself but also gather knowledge that could be used to benefit others.

This adherence to protocol, however, became a source of frustration for some of Steinman’s colleagues. Steinman, for example, refused combined therapies that failed to get regulatory approval, even though he and many of his colleagues felt the combined approach had a higher likelihood of success. He also initially refused to undergo multiple treatments at once because doing so would confuse the data being collected. With time of the essence, colleagues had to argue with Steinman to get him to prioritize the possibility of his health and longevity over proper protocol and clean experimental results. All told, Steinman underwent as many as eight experimental therapies, in addition to surgery and chemotherapy, to combat his disease.

Four and a half years after his cancer diagnosis, he died just three days before the Nobel Prize announcement

During his long career, he received numerous awards and honors, including the prestigious Lasker Award (sometimes referred to as the American Nobel) in 2007. While in the midst of his illness and self-experimentation, he was also nominated for the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and subsequent contributions to immunology research and medicine.

Steinman joked often about surviving long enough to witness the awards announcement, and as late as a week before, the possibility seemed likely. But on September 30, 2011, four and a half years after his cancer diagnosis, he died just three days before the Nobel Prize announcement. He was 68 years old.

Nobel Prize rules generally prohibit the awarding of a prize posthumously, but given the unusual circumstances and unfortunate timing of events, the Nobel Committee ruled to allow the honor to stand. Steinman shares the prize with American immunologist Bruce A. Beutler and French biologist Jules A. Hoffman, also for their work in the area of immunity research.

Although no one can be sure of the efficacy of the dendritic cell-based immunotherapies Steinman underwent or which one(s) might have helped, the Nobel Laureate lived more than four times longer than expected. His decades of work have contributed to clinical therapies for cancer and infectious diseases that will benefit patients for generations to come. And despite those early years of unfocused study, even his self-experimentation laid the groundwork for future treatments, including an immunotherapy against pancreatic cancer based on data gathered during Steinman’s final experiment. – Folks Magazine

Ralph M. Steinman’s research while affiliated with The Rockefeller University and other places

Ralph Steinman died days before it was announced that he was to share the Nobel Prize for Medicine. His work had been part of an unorthodox experiment to save his life, wrote Politico journalist Brett Norman, quoted by BBC, 2011.

When Ralph Steinman learned he had pancreatic cancer, the dogged immunologist put his life’s work to the test.

He launched a life-and-death experiment in the most personal of personalised medicine.

By unlucky coincidence, he had been diagnosed with a disease that might benefit from the therapies he had spent his life researching.

Usually, medical research proceeds at a glacial, thorough pace: cell studies lead to studies in small animals which lead to studies in larger animals, which eventually lead to small, highly-selective clinical trials in humans. But Steinman didn’t have that kind of time.

He did, however, have access to world class facilities, cutting-edge technology, and some of the world’s most brilliant medical minds, thanks to his position as a researcher at Rockefeller University.

So Steinman decided to make his own body the ultimate experiment.

He had removed a piece of the tumour that would eventually kill him. He then trained his immune cells to track down any hint of the tumour that might have escaped the surgery, like putting hounds on a scent.

On Friday, four-and-a-half years after he was diagnosed with a disease that kills the vast majority of its victims in less than one, that experiment came to an end.

Steinman died at the end of a week in which he continued his work in the lab. It was a testament to the undying optimism of the scientific enterprise, to the unrelenting man, and to the limits of both.

An open secret

I joined Rockefeller as a science writer to chronicle the work of its researchers – Steinman included – about halfway through one of his experiments on himself.

His experiment was an open secret on campus, registered with the hospital and aided by a long-time friend and staff physician. The sense of hope was palpable, bound up in respect for the man but also something broader.

Could the painstakingly incremental research that seemed to have so much potential on lab animals this once grant a reprieve from certain death?

Of course everyone was rooting for him, and I had a special interest. Toward the end of 1999, my father had a stomach complaint. Over a few months, the initial diagnosis of an ulcer morphed into a death sentence: inoperable, metastatic cancer of the pancreas.

Pancreatic cancer is often known as the “silent killer” because it usually doesn’t produce truly scary symptoms until it has spread beyond repair. After chemotherapy, my dad bounced back for a few months, but the cancer inevitably did, too. He died at home in the early fall of 2000.

Could Steinman beat it?

I hoped so. The work had promise.

“In the last few years of his life, Dr. Ralph Steinman made himself into an extraordinary human lab experiment, testing a series of unproven therapies – including some he helped to create – as he waged a very personal battle with pancreatic cancer.”

– Reuters

‘Skeptical’ science

In 1973, along with his mentor, Zanvil Cohn, Steinman published the discovery of a new class of cell in the immune system – the dendritic cell. Like many new discoveries, his faced a deeply sceptical reception.

The experiments couldn’t be immediately reproduced, but Steinman was convinced of his discovery. He fought for a decade before immunologists began to broadly recognise the central importance of those cells to their field.

In the past 20 years, the study of dendritic cells has spread to hundreds of labs all over the world. Researchers are exploring how they might be harnessed to fight cancer, HIV and transplant rejection, among other major medical problems.

Dendritic cells are the “sentinel cells” of the mammalian immune system. Named after the Greek word for tree, they develop distinctive probing branches when activated, sweeping their environment in search of unwelcome things – like bacteria, viruses, tumours.

When dendritic cells encounter something they don’t like, they take a physical marker of the invader, called an antigen, and present it to B and T cells, the defenders of the body’ s immune system. Those cells then adapt weapons to identify and destroy the interlopers.

Steinman bet that if he could train his dendritic cells to recognise and tag his cancer, they would be able to convince the T and B cells to do the rest.

Dream deferred

There was no good reason to expect that Steinman could fashion a cure for one of the world’s most vicious cancers in time to save his own life. But it was easy to think it was at least possible. The made-for-Hollywood story of the renegade scientist who fights the establishment to prove his discovery, and then uses it to cure himself, was powerful enough to compel hope.

Unfortunately, the dendritic cell-based treatments didn’t work – at least not well enough.

Training Steinman’s dendritic cells to the tumour did generate a “vigorous immune response to mesothelin, a tumour specific antigen,” said Dr. Sarah Schlesigner, a longtime colleague of Steinman’s who ran the trial.

In other words, while there were significant side effects, the therapy seemed to enable him to work much longer than he otherwise would have. Month after month, he remained at the University, continuing his work.

He survived much longer than expected, and continued his research until the end.

Over time, it wasn’t enough.

At least, not enough to save him.

But the research he pioneered continues – and the scientists who continue his work have an extraordinary example to follow. – BBC, 2011

Also read: RNA Used to Alter DNA, Brain Functions and Behavior (Biohacking p.2)

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

“Imagine a biological computer that operates inside a living cell”
– Dr. Andrew Phillips, head of bio-computation at Microsoft Research.

“The problem we’re trying to solve is really trying to have a more sophisticated diagnosis that can happen automatically inside cells… In this project, we’re trying to use DNA as a programmable material” according to Dr. Neil Dalchau, a scientist at Microsoft Research.

The video will also be made available on our channels the free speech video platforms, see our links

To me, the most striking part in this video is the confirmation that they are after the three-stranded DNA technology Anthony Patch brought up in that sensational 2014 interview, which also earned us a ban from Youtube.

“[Microsoft] are essentially trying to sense, analyze and control molecular information

Georg Seelig, Associate Professor at the Gates-funded University of Washington.

Moderna described mRNA as “an information molecule” and even trademarked the name “mRNA OS” – meaning ‘operating system’, according to bigtechtopia.com
We have Moderna’s head honcho “on tape” describing the mRNA vaccine as “information therapy”:

“Molecular devices made of nucleic acids show great potential for applications ranging from bio-sensing to intelligent nanomedicine. They allow computation to be performed at the molecular scale, while also interfacing directly with the molecular components of living systems. They form structures that are stable inside cells, and their interactions can be precisely controlled by modifying their nucleotide sequences. However, designing correct and robust nucleic acid devices is a major challenge, due to high system complexity and the potential for unwanted interference between molecules in the system. To help address these challenges we have developed the DNA Strand Displacement (DSD) tool, a programming language for designing and simulating computational devices made of DNA. The language uses DNA strand displacement as the main computational mechanism, which allows devices to be designed solely in terms of nucleic acids. DSD is a first step towards the development of design and analysis tools for DNA strand displacement, and complements the emergence of novel implementation strategies for DNA computing.”

Microsoft Research

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

Not a word from me, learn from experts and manufacturers. And Bill Gates.

IF YOUTUBE TAKES DOWN THE VIDEO, THERE ARE ALTERNATIVE UPLOADS ON LBRY AND BRIGHTEON

Dr. David Martin quoted from a Weston A. Price podcast

Obviously, I’m never recommending anything from Pharmafia ever, I’m just highlighting their BS.

Source: BBC
Source: BBC

Also this:
WHY DID MODERNA UNLIST THIS VIDEO PRESENTATION OF THEIR COVID-19 “VACCINE”?! EVERYONE NEEDS TO WATCH IT

UPDATE:

I unearthed a 2017 Ted Talk featuring the current Moderna boss Tal Zaks, where he describes the mRNA technology that was first meant to treat cancer, he call it “information therapy”, see for yourselves:

Ah, and also this:

UPDATE 2:

DR. TENPENNY EXCELLENTLY SUMS UP THE CASE AGAINST mRNA TECHNOLOGY, SOLIDIFYING EVERYTHING WE’VE EXPOSED:

WE’VE JUST GOT A BAN FROM YOUTUBE FOR TRYING TO MIRROR THIS VIDEO ON OUR CHANNEL, BUT THAT’S ANOTHER STORY. SO FAR IT HOLDS ON THE ORIGINAL CHANNEL, IF THEY TAKE IT DOWN, IT’S ALREADY BACKED ON OUR ODYSEE CHANNEL, SEE THE LINKS PAGE 😉

UPDATE: ANOTHER OPEN ADMISSION: APRIL 2021

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

It’s published on their site though…

Link

Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
But we’re underfunded for June, when we have heavy annual bills to pay for the websites, not counting the countless hours of work. Next target would be adding new features and plugins to the website and better equipment for faster work and more complex video productions.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them